Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atyr Pharma Inc (NQ: LIFE )

1.640 -0.020 (-1.20%)
Streaming Delayed Price Updated: 10:50 AM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 76,533
Open 1.690
Bid (Size) 1.640 (57)
Ask (Size) 1.650 (5)
Prev. Close 1.660
Today's Range 1.640 - 1.690
52wk Range 1.080 - 2.700
Shares Outstanding 54,291,754
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
aTyr Pharma to Present at Upcoming Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024
LIFE stock results show that aTyr Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+9.70%
+9.70%
1 Month
-10.38%
-10.38%
3 Month
-3.53%
-3.53%
6 Month
+28.12%
+28.12%
1 Year
-23.36%
-23.36%

More News

Read More
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Recap: aTyr Pharma Q4 Earnings
Via Benzinga
aTyr Pharma's Earnings Outlook
Via Benzinga
Analyst Expectations for aTyr Pharma's Future
Via Benzinga
aTyr Pharma to Participate in April Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
Via InvestorPlace
LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023
Via InvestorPlace
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
From aTyr Pharma, Inc.
Via GlobeNewswire
Earnings Scheduled For March 14, 2024
Via Benzinga
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
From aTyr Pharma, Inc.
Via GlobeNewswire
The 3 Best Penny Stocks to Buy in February 2024
Via InvestorPlace
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
From aTyr Pharma, Inc.
Via GlobeNewswire
Beat of Life Entertainment's 'Diya Jalao Roshni Lao' Campaign: Lighting Up Lives and Preserving Tradition!
Via IssueWire
Topics Religion
Exposures Religion
aTyr Pharma to Present at November Investor Conferences
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
From aTyr Pharma, Inc.
Via GlobeNewswire
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
From aTyr Pharma, Inc.
Via GlobeNewswire
$12M Bet On This Trucking Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
aTyr Pharma's Cash Runway Secured till 2026, Despite Lack of Material Catalysts: Oppenheimer Analyst
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023
Via Benzinga
7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.